...
机译:Erlotinib治疗复发或转移皮肤鳞状细胞癌:单臂2阶段临床试验
Division of Hematology and Oncology Moores Cancer CenterUniversity of California–San DiegoLa Jolla;
Department of Thoracic/Head and Neck Medical OncologyThe University of Texas MD Anderson Cancer;
Department of Thoracic/Head and Neck Medical OncologyThe University of Texas MD Anderson Cancer;
Department of Thoracic/Head and Neck Medical OncologyThe University of Texas MD Anderson Cancer;
Department of BiostatisticsThe University of Texas MD Anderson Cancer CenterHouston Texas;
Department of Thoracic/Head and Neck Medical OncologyThe University of Texas MD Anderson Cancer;
squamous cell carcinoma; skin cancer; erlotinib; epidermal growth factor receptor; anti‐neoplastic agents;
机译:Erlotinib治疗复发或转移皮肤鳞状细胞癌:单臂2阶段临床试验
机译:顺铂,多西他赛和厄洛替尼在复发和/或转移性头颈部鳞状细胞癌患者中的单臂II期研究
机译:患有复发性和/或转移头和颈部鳞状细胞癌患者的单臂,Coisplatin,Docetaxel和Erlotinib的单臂研究
机译:患者临床试验与患有转移和/或复发性固体瘤的患者的HER-2 B细胞嵌合和多型肽疫苗
机译:皮肤透明细胞鳞状细胞癌原位:临床,形态学和免疫组化特征。
机译:厄洛替尼治疗复发或转移性皮肤鳞状细胞癌:单臂II期临床试验
机译:Erlotinib治疗复发性或转移皮肤鳞状细胞癌:单臂阶段2临床试验